Keyword Search
 

2018 | 2017 | 2016 | 2015 | 2014
Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™

Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ to Hold Third Quarter 2016 Financial Results Conference Call on Wednesday, November 9, 2016

Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer

Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases

Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases

Ocular Therapeutix™ Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix™ to Participate in the Morgan Stanley Global Healthcare Conference

Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)

Ocular Therapeutix™ Provides Update on NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain

Ocular Therapeutix™ to Report Second Quarter 2016 Financial Results

Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain

Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

Ocular Therapeutix™ Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA™ for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update

Ocular Therapeutix™ to Report First Quarter 2016 Financial Results

Ocular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension

Ocular Therapeutix™ to Host Investor Day on April 6, 2016

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2015 Financial Results

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2015 Financial Results

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension

Ocular Therapeutix™ Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer